A study to evaluate metastatic melanoma survivors in terms of health-related quality of life, immune-related adverse events and exposure to immunosuppressive agents in a large single centre in the UK
Latest Information Update: 15 Apr 2020
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 15 Apr 2020 New trial record